IPA-CJC-MIX

Ipamorelin / CJC-1295 5+5mg Mix

Longevity

Ipamorelin / CJC-1295 - a synergistic dual-peptide blend combining a selective GH secretagogue with a GHRH analogue. Among the most studied peptide pairs for GH/IGF-1 axis modulation, body composition research, and anti-ageing mechanism studies.

64,99 €

≥99% HPLC purity

Third-party tested · Discreet packaging · Ships from the EU

Specifications
SKU
IPA-CJC-MIX
Usage Notes

This compound is intended exclusively for in vitro research. Refer to peer-reviewed literature for dosing protocols and experimental methodologies.

Disclaimer: Not for human or animal consumption. Not approved by EMA or FDA.

For in vitro research use only. Not for human or animal consumption.

Ipamorelin / CJC-1295 5+5mg Mix

Research profile

Overview

This formulation combines two peptides studied within the growth hormone signalling axis: Ipamorelin, a selective growth hormone secretagogue receptor (GHS-R1a) agonist, and CJC-1295, a modified growth hormone-releasing hormone (GHRH) analogue incorporating Drug Affinity Complex (DAC) technology. The compounds act through distinct signalling pathways and are investigated in research concerning growth hormone secretion and the GH/IGF-1 axis.

Key Research Areas

  1. Growth Hormone Signalling

    Ipamorelin and CJC-1295 are studied through different receptor pathways involved in the regulation of growth hormone secretion.

  2. GHS-R1a Agonism

    Ipamorelin acts as an agonist of the growth hormone secretagogue receptor and has been investigated for its effects on pulsatile GH release.

  3. GHRH Receptor Signalling

    CJC-1295 is a modified GHRH analogue studied for its ability to stimulate pituitary somatotroph activity and influence downstream GH/IGF-1 signalling.

  4. Extended Peptide Activity

    CJC-1295 with DAC was designed to bind circulating albumin, substantially extending its biological persistence compared with unmodified GHRH peptides.

  5. Combined GH-Axis Research

    The combination provides a research model for investigating simultaneous GHS-R and GHRH receptor signalling and their effects on the somatotropic axis.

Specifications

Ipamorelin CAS 170851-70-4
Ipamorelin Molecular Weight ~711.86 g/mol
CJC-1295 CAS 863288-34-0
CJC-1295 Molecular Weight ~3647.28 g/mol
Purity ≥99% (HPLC verified)
Form Lyophilised powder, peptide blend per vial (3ml)

For in vitro laboratory research use only. Not for human or animal administration.

Reviews

There are no reviews yet.

Be the first to review “Ipamorelin / CJC-1295 5+5mg Mix”

Your email address will not be published. Required fields are marked *